• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Clinical trials

Clinical trial protocol synopses

Home > Research and development > Clinical trials

Clinical trial protocol synopses

  • Clinical trials
  • Clinical trial protocol synopses

Browse our clinical trial protocol synopses

Loading…
All
Chagas disease
Cryptococcal meningitis
Cutaneous leishmaniasis
Filaria: river blindness
Hepatitis C
Mycetoma
Pandemic Preparedness
Sleeping sickness
Visceral leishmaniasis
  • Cutaneous leishmaniasis
LXE408 Novartis for CL
Translation project phase
DNDi-LXE408-03-CL / CLXE408C12201R
Efficacy, safety, and pharmacokinetics of two LXE408 regimens for localized cutaneous leishmaniasis in the region of the Americas
Protocol synopsis
  • Latin America
  • Filaria: river blindness
clinical trials icon
DNDI-TYL-01
Tylamac phase-II trial for treatment of onchocerciasis
Protocol synopsis
  • Democratic Republic of Congo, Africa
  • Cutaneous leishmaniasis
Miltefosine + thermotherapy for cutaneous leishmaniasis
clinical trials icon
DNDi-MILT-08-CL
Efficacy and safety of thermotherapy plus miltefosine for cutaneous leishmaniasis in South America
Protocol synopsis
  • Colombia, Latin America, Peru
  • Hepatitis C
Ravidasvir + sofosbuvir
Translation project phase
DNDi-RDV-04-HCV
Bioequivalence study of test and reference ravidasvir for chronic HCV (in healthy fed participants)
Protocol synopsis
  • Asia, Malaysia
  • Sleeping sickness
Acoziborole
Translation project phase
DNDi-OXA-07-HAT
A drug-drug interaction study of acoziborole for T. b. gambiense sleeping sickness (in healthy male participants)
Protocol synopsis
  • Asia, Malaysia
  • Sleeping sickness
Acoziborole
clinical trials icon
DNDi-OXA-05-HAT
Pharmacokinetics, efficacy, safety, and tolerability of acoziborole in children with T. b. gambiense sleeping sickness
Protocol synopsis
  • Africa, Democratic Republic of Congo
  • Sleeping sickness
Acoziborole
clinical trials icon
DNDi-OXA-04-HAT
Safety and tolerability of acoziborole for seropositive non-parisitologically confirmed T. b. gambiense sleeping sickness
Protocol synopsis
  • Africa, Democratic Republic of Congo, Guinea
  • Visceral leishmaniasis
Miltefosine + Paromomycin combination (Africa)
clinical trials icon
DNDi-MILT/PM-01-VL
Efficacy and safety of paromomycin plus miltefosine or sodium stibogluconate for visceral leishmaniasis in Africa
Protocol synopsis
  • Africa, Ethiopia, Kenya, Uganda, Sudan
  • Visceral leishmaniasis
LXE408 Novartis for VL
Translation project phase
DNDi-LXE408-02-VL / CLXE408A12202R
Efficacy, safety, and pharmacokinetics of LXE408 for primary visceral leishmaniasis in Ethiopia
Protocol synopsis
  • Africa, Ethiopia
  • Visceral leishmaniasis
LXE408 Novartis for VL
Translation project phase
DNDi-LXE408-01-VL / CLXE408A12201R
Efficacy and safety of two LXE408 regimens for primary visceral leishmaniasis in India
Protocol synopsis
  • Asia, India
  • Hepatitis C
Ravidasvir + sofosbuvir
Translation project phase
DNDi-RDV-02-HCV
Bioequivalence study of test and reference ravidasvir tablets for chronic HCV (in healthy fed participants)
Protocol synopsis
  • Asia, Malaysia
  • Chagas disease
Fexinidazole for Chagas
clinical trials icon
DNDi-FEX-12-CH
Efficacy and safety of fexinidazole for undetermined chronic Chagas disease
Protocol synopsis
  • Europe, Spain
  • Filaria: river blindness
Emodepside
Translation project phase
DNDI-EMO-03
Tolerability, safety, and bioavailability study of immediate release emodepside for river blindness (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Filaria: river blindness
Emodepside
Translation project phase
DNDI-EMO-02
Safety, tolerability, and pharmacokinetics of emodepside for river blindness (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Cutaneous leishmaniasis
CpG-D35 (DNDI-2319)
Translation project phase
DNDi-CpG-001
Safety, tolerability, pharmacokinetics, and pharmacodynamics of CpG ODN D35 for cutaneous leishmaniasis (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Cryptococcal meningitis
5FC HIV-Crypto
Translation project phase
DNDi-5FC-02-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fed participants)
Protocol synopsis
  • Africa, South Africa
  • Cryptococcal meningitis
5FC HIV-Crypto
Translation project phase
DNDi-5FC-01-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fasting participants)
Protocol synopsis
  • Africa, South Africa
  • Cutaneous leishmaniasis, Visceral leishmaniasis
DNDI-6148
Translation project phase
DNDi-6148-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-6148 for visceral leishmaniasis (in healthy participants)
Protocol synopsis
  • Europe, France
  • Cutaneous leishmaniasis, Visceral leishmaniasis
DNDI-0690
Translation project phase
DNDi‐0690‐02
Safety, tolerability, and pharmacokinetics of multiple dose DNDI-0690 for visceral leishmaniasis (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Visceral leishmaniasis
DNDI-0690
Translation project phase
DNDi-0690-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-0690 for visceral and cutaneous leishmaniasis (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Pandemic Preparedness
ANTICOV
clinical trials icon
ANTICOV
Platform trial of efficacy and safety of several therapies for mild / moderate COVID-19
Clinical trial protocol
  • Africa, Ghana, Guinea, Kenya, Sudan, Uganda, Mali, Brazil, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Latin America, Tanzania, Mozambique
  • Visceral leishmaniasis
New treatments for PKDL (Eastern Africa)
clinical trials icon
DNDi-MILT COMB-02-PKDL
Efficacy and safety of miltefosine plus either liposomal amphotericin B or paromomycin for PKDL in Sudan
Protocol synopsis
  • Africa, Sudan
  • Visceral leishmaniasis
New treatments for PKDL (South Asia)
clinical trials icon
DNDi-MILT COMB-01-PKDL
Efficacy and safety of liposomal amphotericin B alone and in combination with miltefosine for PKDL in Asia
Clinical trial protocol Protocol synopsis
  • Asia, Bangladesh, India
  • Mycetoma
Fosravuconazole
clinical trials icon
DNDi-FOSR-04-MYC
Comparative efficacy of two fosravuconazole doses with itraconazole for eumycetoma, in combination with surgery
Clinical trial protocol
  • Africa, Sudan
  • Chagas disease
New benznidazole regimens
clinical trials icon
DNDi-CH-E1224-003
Efficacy and safety of shorter benznidazole regimens and E1224 for chronic Chagas disease
Clinical trial protocol
  • Bolivia, Latin America
  • Hepatitis C
Ravidasvir + sofosbuvir
clinical trials icon
DNDi-SOF/RDV-01-HCV
Efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for chronic HCV
Clinical trial protocol
  • Asia, Thailand, Malaysia
  • Sleeping sickness
Acoziborole
Translation project phase
DNDi-OXA-03-HAT
Absorption, metabolism, and excretion of acoziborole for sleeping sickness (in healthy participants)
Protocol synopsis
  • Europe, United Kingdom
  • Sleeping sickness
Acoziborole
clinical trials icon
DNDi-OXA-02-HAT
Efficacy and safety of acoziborole for T.b. gambiense sleeping sickness
Clinical trial protocol
  • Africa, Democratic Republic of Congo, Guinea
  • Sleeping sickness
Fexinidazole for T.b. gambiense
Discovery project phase
DNDi-HAT-FEX-006
Efficacy and safety of fexinidazole for T. b. gambiense sleeping sickness in children
Clinical trial protocol
  • Africa, Democratic Republic of Congo
  • Sleeping sickness
Fexinidazole for T.b. gambiense
clinical trials icon
DNDi-HAT-FEX-005
Efficacy and safety of fexinidazole for stage 1 & early stage 2 T. b. gambiense sleeping sickness
Clinical trial protocol
  • Africa, Democratic Republic of Congo
  • Sleeping sickness
Fexinidazole for T.b. gambiense
clinical trials icon
DNDi-FEX-09-HAT
Efficacy, safety and adherence with fexinidazole for any stage of T.b. gambiense sleeping sickness
Clinical trial protocol
  • Democratic Republic of Congo, Guinea, Africa
  • Sleeping sickness
Fexinidazole for T.b. rhodesiense
clinical trials icon
DNDi-FEX-07-HAT
Efficacy and safety of fexinidazole for T.b. rhodesiense sleeping sickness
Clinical trial protocol Protocol synopsis
  • Africa, Uganda, Malawi
  • Sleeping sickness
Fexinidazole for T.b. gambiense
clinical trials icon
DNDi-FEX-004
Efficacy and safety of fexinidazole for late-stage T.b. gambiense sleeping sickness
Protocol synopsis
  • Africa

To request access to data from any of DNDi’s clinical trials, please visit the website of our data-sharing partner, Vivli, to make a data request. 

Project portfolio

We are working on more than 40 research and treatment access projects, including more than 20 focused on identifying or developing new chemical entities.

see portfolio

Scientific articles

Loading…
Scientific articles
9 May 2025

Epidemiological, clinical and etiological treatment aspects in the Chagas clinic of the municipality of Comapa – Jutiapa, Guatemala

Acta Tropica
Scientific articles
15 May 2025

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study

Journal of Chromatography B
Scientific articles
13 May 2025

Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease

PLOS Neglected Tropical Diseases
Scientific articles
9 May 2025

Efficient constitution of a library of rotenoid analogs active against Trypanosoma cruzi from a digitalized plant extract collection

RSC Advances
see all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License